Novavax (NVAX) closed at $8.84 in the latest trading session, marking a +2.31% move from the prior day. This change outpaced the S&P 500's 1.2% gain on the day. Meanwhile, the Dow gained 1.79%, and ...

In late March 2026, Novavax appointed Dr. Robert Walker as Executive Vice President and Head of R&D, while activist investor Shah Capital renewed its campaign to overhaul the company’s board, ...

Chief among its criticisms is Novavax's failure to build sales of its protein-based COVID-19 vaccine Nuvaxovid/Covovax, a ...

Shah Capital, which has agitated for change at the vaccine maker for years, is calling on fellow shareholders to end what it ...

Wondering whether Novavax at about US$7.98 is a bargain or a value trap? This article walks through the key signals that ...

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

"Your tenure has overseen a DESTRUCTION of shareholder value—a direct result of chronic operational shortcomings and failures ...

Shah Capital plans “against” votes on directors and say-on-pay, while seeking to sway ISS and Glass Lewis rather than running ...

Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate. Leveraging Novavax’s recombinant, protein-based nanoparticle technology and ...

The MarketWatch News Department was not involved in the creation of this content. -- Non-exclusive license allows for development by Pfizer to utilize Matrix-M(R) for up to two disease areas with its ...